The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework
This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
By reducing fractional catabolic rate and by producing a large, cholesterol rich HDL molecule which could not easily be cleared by hepatic HDL receptors, our research group in Cincinnati thought from the beginning that the CETP inhibitors AS A CLASS would fail, and might even be proatherogenic. Regrettably,...
1. Atrial fibrillation ablation is one of the fastest growing procedural areas in cardiac electrophysiology.
2. There is a need to achieve a higher success rate than is currently being observe.
3. The majority of afib ablations are performed using radiofrequency energy.
4. Other ablation technologies...
1. The chronicle device is a stand alone hemodynamic monitor that is implanted in a similar fashion as a pacemaker. It includes a wire that is capable of measuring blood pressure in the lungs. This pressure measurement may serve as a early warning of worsening heart...
1. There are no new drugs designed to raise HDL anywhere close to coming to market2. Niacin remains the best agent on the market (in terms of HDL raising and improved outcomes) and is undergoing some potential improvement to reduce annoying side effects3. There remains great debate as to what the biological...
The surrogate atherosclerosis end point studies with torcetrapib promise to give important, but likely complex clues regarding its paradoxical increase in CVD events and mortality. Some promising HDL-raising approaches still appear to be eluding pharmaceutical R&D.Niacin promises to be a big winner...
1. Pfizer Inc, the pharmaceutical giant, halted late-stage trials of the HDL increasing drug torcetrapib after investigators discovered that it increased heart problems and increased death rates in the treated population. 2. Niacin, a B vitamin that increases HDL (the good cholesterol) up to 35%, has...
With the demise of the clinical development of Torcetrapib we are forced to reevaluate our views of HDL raising.We have had good HDL-raising drugs for many years, but they have gone underutilized and underappreciated.Many cardiologists (often supposed by others to be lipid experts) have never or rarely...
Niacin is one of the best drugs to treat hyperlipidemia in our armamentarium. It raises HDL (good CHL), and lowers both LDL and triglycerides, while statins essentially only target LDL metabolism. It is also one of the worst in terms of side effects. While LDL (bad cholesterol) is the primary target,...